Urology Doctors in Midland, TX Accepting Medicare

6 Urology doctors found. Showing 1 - 6

Nipank N Shroff, MD PA Urology Medicare: Not Enrolled in Medicare Practice Location: 4937 Rustic Trl, Midland Urology Ctr, Midland, TX 79707 Phone: 432-699-2526    Fax: 432-699-1141

Aaron B Stike, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2706 W Cuthbert Ave Ste C, Midland, TX 79701 Phone: 432-687-0311    Fax: 432-687-0312

Daniel Khouri, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1200 W Wall St, Midland, TX 79701 Phone: 432-682-0574    Fax: 432-682-8939

John L Saba, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 3604 Trinity Dr, Midland, TX 79707 Phone: 432-689-4744    Fax: 432-689-4744

Michael John Dragun, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2706 W Cuthbert Ave Ste C, Midland, TX 79701 Phone: 432-687-0311    Fax: 432-687-0312

John Barry Staub, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2706 W Cuthbert Ave Ste C, Midland, TX 79701 Phone: 432-687-0311    Fax: 432-687-0312

News Archive

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

New research in mice shows that two commonly used gout medications, which target uric acid and adenosine triphosphate, may offer protection from alcohol-induced liver disease and inflammation.

Adherence to lifestyle recommendations reduces risk of colorectal cancer by 23%

Almost a quarter of colorectal (bowel) cancer cases could be prevented if people followed healthy lifestyle advice in five areas including diet and exercise, says a new study published on bmj.com today.

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

Read more Medical News

› Verified 2 days ago